CHF trial mythbusting, page-3

  1. 3,053 Posts.
    lightbulb Created with Sketch. 2
    I agree that MSB should unambiguously state if Teva saw the yes/no from the surrogate endpoint analysis, and they should release it to the ASX, not via an email.

    I haven't seen any FDA ruling that this data couldn't be released to Teva, especially since it has been part of the trial design from the beginning. Can you find a source?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.68
Change
-0.160(8.70%)
Mkt cap ! $2.143B
Open High Low Value Volume
$1.81 $1.83 $1.68 $11.30M 6.548M

Buyers (Bids)

No. Vol. Price($)
22 82773 $1.68
 

Sellers (Offers)

Price($) Vol. No.
$1.68 19054 41
View Market Depth
Last trade - 14.48pm 02/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.